Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type

References

• Cancer Stat Facts: Lung and Bronchus Cancer. National Cancer Institute: surveillance, epidemiology and end results program [accessed 2023 Jul]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html
   Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2018;29(Suppl 4):iv192–iv237. doi: 10.1093/annonc/mdy275.
   PubMed Web of Science ®Google Scholar
• Besse B, Adjei A, Baas P, et al. 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475–1484. doi: 10.1093/annonc/mdu123.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Lung cancer survival rates; [accessed 2023 April 5]. Available from: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html
   Google Scholar
• Zhang Y-L, Yuan J-Q, Wang K-F, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–78993. doi: 10.18632/oncotarget.12587.
   PubMedGoogle Scholar
• Li WY, Zhao TT, Xu HM, et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):145. doi: 10.1186/s12885-019-5331-z.
   PubMedGoogle Scholar
• Fang S, Wang Z. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther. 2014;8:1595–1611. doi: 10.2147/dddt.S69690.
   PubMed Web of Science ®Google Scholar
• Suda K, Mitsudomi T, Shintani Y, et al. Clinical impacts of EGFR mutation status: analysis of 5780 surgically resected lung cancer cases. Ann Thorac Surg. 2021;111(1):269–276. doi: 10.1016/j.athoracsur.2020.05.041.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer; [updated 2023 Apr 13; accessed 2023 Jul]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Graham RP, Treece AL, Lindeman NI, et al. Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med. 2017;142(2):163–167. doi: 10.5858/arpa.2016-0579-CP.
   PubMed Web of Science ®Google Scholar
• Ullas B, Bivas B, Kumar P, et al. Differential clinicopathological features, treatments and outcomes in patients with exon 19 deletion and exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. BMJ Open Respir Res. 2023;10(1):e001492. doi: 10.1136/bmjresp-2022-001492.
   PubMed Web of Science ®Google Scholar
• Sheng M, Wang F, Zhao Y, et al. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. Eur J Clin Pharmacol. 2016;72(1):1–11. doi: 10.1007/s00228-015-1966-0.
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhu M, Li Y, et al. Association between EGFR exon 19 or exon 21 mutations and survival rates after first‑line EGFR‑TKI treatment in patients with non‑small cell lung cancer. Mol Clin Oncol. 2019;11(3):301–308. doi: 10.3892/mco.2019.1881.
   PubMed Web of Science ®Google Scholar
• Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLoS One. 2021;16(3):e0247620. doi: 10.1371/journal.pone.0247620.
   PubMed Web of Science ®Google Scholar
• Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4(1):5. doi: 10.1038/s41392-019-0038-9.
   PubMed Web of Science ®Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Reg Health Eur. 2021;3:100060. doi: 10.1016/j.lanepe.2021.100060.
   PubMedGoogle Scholar
• National Cancer Institute. Financial burden of cancer care; [accessed 2023 May 3]. Available from: https://progressreport.cancer.gov/after/economic_burden
   Google Scholar
• Vanderpoel J, Emond B, Ghelerter I, et al. Healthcare resource utilization and costs in patients with EGFR-Mutated advanced non-small cell lung cancer receiving first-Line treatment in the United States: an insurance claims-based descriptive analysis. Pharmacoecon Open. 2023;7(4):617–626. doi: 10.1007/s41669-023-00407-0.
   PubMed Web of Science ®Google Scholar
• Albaba H, Lim C, Leighl NB. Economic considerations in the use of novel targeted therapies for lung cancer: review of current literature. Pharmacoeconomics. 2017;35(12):1195–1209. doi: 10.1007/s40273-017-0563-8.
   PubMed Web of Science ®Google Scholar
• Shen C, Holguin RAP, Schaefer E, et al. Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma. BMC Health Serv Res. 2022;22(1):470. doi: 10.1186/s12913-022-07857-y.
   PubMed Web of Science ®Google Scholar
• Samuelsen C, Lim J, Golembesky A, et al. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States. J Med Econ. 2020;23(1):48–53. doi: 10.1080/13696998.2019.1645681.
   PubMed Web of Science ®Google Scholar
• Hou J, Li H, Ma S, et al. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. Biomark Res. 2022;10(1):21. doi: 10.1186/s40364-022-00372-6.
   PubMed Web of Science ®Google Scholar
• Huse D, Russo P, Vasey J. Expanding the evidence base in outcomes research: linking electronic medical records and claims data. ISPOR Connect. 2013;19(3):5–7.
   Google Scholar
• US Bureau of Labor Statistics. Medical care in U.S. city average, all urban consumers, seasonally adjusted. 2023 [accessed 2023 Aug 15]. Available from: https://data.bls.gov/timeseries/CUSR0000SAM
   Google Scholar
• ASCO. Lung cancer - non-small cell: statistics; [accessed 2022 Sept 30]. Available from: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics
   Google Scholar
• Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220–229. doi: 10.1158/1535-7163.Mct-12-0620.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179–184. doi: 10.1097/JTO.0b013e3182779d18.
   PubMed Web of Science ®Google Scholar
• Tamura T, Kurishima K, Nakazawa K, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol. Jan 2015;3(1):217–221. doi: 10.3892/mco.2014.410.
   PubMedGoogle Scholar
• Carroll R, Bortolini M, Calleja A, et al. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis. BMC Cancer. 2022;22(1):255. doi: 10.1186/s12885-022-09342-5.
   PubMed Web of Science ®Google Scholar
• Chen Y, Deng J, Liu Y, et al. Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Ann Transl Med. 2021;9(3):206–206. doi: 10.21037/atm-20-2925.
   PubMed Web of Science ®Google Scholar
• Olivier T, Prasad V. Amivantamab and mobocertinib in exon 20 insertions EGFR mutant lung cancer, challenge to the current guidelines. Transl Oncol. 2022;23:101475. doi: 10.1016/j.tranon.2022.101475.
   PubMed Web of Science ®Google Scholar
• Takeda Press Releases. Takeda provides update on EXKIVITY® (mobocertinib); [accessed 2023 Oct]. Available from: https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Provides-Update-on-EXKIVITY-mobocertinib/
   Google Scholar
• Riely GJ, Lovly CM, Messina CG, et al. Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. J Clin Oncol. 2019;37(15_suppl):9062–9062. doi: 10.1200/JCO.2019.37.15_suppl.9062.
   Google Scholar
• Chelabi S, Mignard X, Leroy K, et al. EGFR exon 20 insertion in metastatic non-small-cell lung cancer: survival and clinical efficacy of EGFR tyrosine-kinase inhibitor and chemotherapy. Cancers. 2021;13(20):5132. doi: 10.3390/cancers13205132.
   PubMed Web of Science ®Google Scholar
• O'Sullivan DE, Jarada TN, Yusuf A, et al. Prevalence, treatment patterns, and outcomes of individuals with EGFR positive metastatic non-small cell lung cancer in a Canadian real-world setting: a comparison of exon 19 deletion, L858R, and exon 20 insertion EGFR mutation carriers. Curr Oncol. 2022;29(10):7198–7208. doi: 10.3390/curroncol29100567.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Supplement approval: NDA 208065/S-008; [accessed 2023 Sept 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208065Orig1s008ltr.pdf
   Google Scholar
• Gibson AJW, Li H, D'Silva A, et al. Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer. Med Oncol. 2018;35(9):117. doi: 10.1007/s12032-018-1182-8.
   PubMed Web of Science ®Google Scholar
• Yang W, Gao Y, Li X, et al. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study. World J Surg Oncol. 2017;15(1):197. doi: 10.1186/s12957-017-1251-z.
   PubMedGoogle Scholar
• Giuliani J, Bonetti A. Pharmacologic costs of tyrosine kinase inhibitors in first-Line therapy for advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutations: a review of pivotal phase III randomized controlled trials. Clin Lung Cancer. 2016;17(2):91–94. doi: 10.1016/j.cllc.2015.12.005.
   PubMed Web of Science ®Google Scholar
• Choi YC, Zhang D, Tyczynski JE. Comparison between health insurance claims and electronic health records (EHRs) for metastatic non-small-cell lung cancer (NSCLC) patient characteristics and treatment patterns: a retrospective cohort study. Drugs Real World Outcomes. 2021;8(4):577–587. doi: 10.1007/s40801-021-00269-0.
   PubMedGoogle Scholar